Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial.
Tay J, Allan DS, Chatelain E, Coyle D, Elemary M, Fulford A, Petrcich W, Ramsay T, Walker I, Xenocostas A, Tinmouth A, Fergusson D. Tay J, et al. Among authors: xenocostas a. J Clin Oncol. 2020 May 1;38(13):1463-1473. doi: 10.1200/JCO.19.01836. Epub 2020 Feb 21. J Clin Oncol. 2020. PMID: 32083994 Clinical Trial.
Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.
Villa D, Crump M, Panzarella T, Savage KJ, Toze CL, Stewart DA, MacDonald DA, Buckstein R, Lee C, Alzahrani M, Rubinger M, Foley R, Xenocostas A, Sabloff M, Muccilli A, Chua N, Couture F, Larouche JF, Cohen S, Connors JM, Ambler K, Al-Tourah A, Ramadan KM, Kuruvilla J. Villa D, et al. Among authors: xenocostas a. J Clin Oncol. 2013 Mar 20;31(9):1164-71. doi: 10.1200/JCO.2012.44.0693. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401459
Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
Sheppard D, Tay J, Palmer D, Xenocostas A, Doulaverakis C, Huebsch L, McDiarmid S, Tinmouth A, Mallick R, Martin L, Birch P, Hamelin L, Allan D, Bredeson C. Sheppard D, et al. Among authors: xenocostas a. Biol Blood Marrow Transplant. 2016 Apr;22(4):763-767. doi: 10.1016/j.bbmt.2015.11.016. Epub 2015 Nov 28. Biol Blood Marrow Transplant. 2016. PMID: 26643030 Free article.
Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche.
Boyd AL, Reid JC, Salci KR, Aslostovar L, Benoit YD, Shapovalova Z, Nakanishi M, Porras DP, Almakadi M, Campbell CJV, Jackson MF, Ross CA, Foley R, Leber B, Allan DS, Sabloff M, Xenocostas A, Collins TJ, Bhatia M. Boyd AL, et al. Among authors: xenocostas a. Nat Cell Biol. 2017 Nov;19(11):1336-1347. doi: 10.1038/ncb3625. Epub 2017 Oct 16. Nat Cell Biol. 2017. PMID: 29035359
A Multicenter, Retrospective Study Evaluating Clinical Outcomes of Ruxolitinib Therapy In Heavily Pretreated Chronic GVHD Patients With Steroid Failure.
White J, Elemary M, Linn SM, Novitzky-Basso I, Culos S, Tan SK, Kelly K, Deotare U, Xenocostas A, Hamad N, Law A, Kumar R, Kim DDH. White J, et al. Among authors: xenocostas a. Transplant Cell Ther. 2023 Feb;29(2):120.e1-120.e9. doi: 10.1016/j.jtct.2022.11.025. Epub 2022 Nov 30. Transplant Cell Ther. 2023. PMID: 36460202 Free article. Clinical Trial.
Propensity score matching analysis comparing the efficacy of Ruxolitinib to historical controls in second-line or beyond treatment for chronic GvHD after steroid failure.
Novitzky-Basso I, Linn SM, White J, Elemary M, Xenocostas A, Deotare U, Kelly K, Hamad N, Tan S, Culos S, Law A, Kumar R, Mattsson J, Kim DDH. Novitzky-Basso I, et al. Among authors: xenocostas a. Bone Marrow Transplant. 2023 Sep;58(9):1024-1032. doi: 10.1038/s41409-023-02020-5. Epub 2023 Jun 26. Bone Marrow Transplant. 2023. PMID: 37365296
95 results